--------------------------
                                                             OMB APPROVAL

                                                      OMB Number:      3235-0145
                                                      Expires: February 28, 2009
                                                      Estimated average burden
                                                      hours per response    10.4
                                                      --------------------------



                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  SCHEDULE 13G

                    UNDER THE SECURITIES EXCHANGE ACT OF 1934

                               (AMENDMENT NO. 1)*




                           RIGEL PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
                                (Name of Issuer)



                                  COMMON STOCK
--------------------------------------------------------------------------------
                         (Title of Class of Securities)



                                    766559603
--------------------------------------------------------------------------------
                                 (CUSIP Number)



                                DECEMBER 31, 2007
--------------------------------------------------------------------------------
             (Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

[ ]   Rule 13d-1(b)

[X]   Rule 13d-1(c)

[ ]   Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).

PERSONS WHO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE
NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL
NUMBER.



-------------------                                           ------------------
CUSIP No. 766559603                   13G/A                   Page 2 of 10 Pages
-------------------                                           ------------------


1.       NAMES OF REPORTING PERSONS

         Great Point Partners, LLC

         I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

         37-1475292

2.       CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

         (a)      [ ]

         (b)      [ ]

--------------------------------------------------------------------------------
3.       SEC USE ONLY


--------------------------------------------------------------------------------

4.       CITIZENSHIP OR PLACE OF ORGANIZATION

         USA

NUMBER OF SHARES           5.       SOLE VOTING POWER
  BENEFICIALLY
 OWNED BY EACH             6.       SHARED VOTING POWER
REPORTING PERSON                                            656,900
      WITH                 7.       SOLE DISPOSITIVE POWER

                           8.       SHARED DISPOSITIVE POWER
                                                            656,900

9.       AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                  656,900

10.      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
         SHARES (See Instructions)                                           [ ]

11.      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

                  2.12%

12.      TYPE OF REPORTING PERSON (See Instructions)

                  OO



-------------------                                           ------------------
CUSIP No. 766559603                   13G/A                   Page 3 of 10 Pages
-------------------                                           ------------------


1.       NAMES OF REPORTING PERSONS

         Dr. Jeffrey R. Jay, M.D.

         I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):



2.       CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

         (a)      [ ]

         (b)      [ ]

--------------------------------------------------------------------------------
3.       SEC USE ONLY


--------------------------------------------------------------------------------

4.       CITIZENSHIP OR PLACE OF ORGANIZATION

         USA

NUMBER OF SHARES           5.       SOLE VOTING POWER
  BENEFICIALLY                                              0
 OWNED BY EACH             6.       SHARED VOTING POWER
REPORTING PERSON                                            656,900
      WITH                 7.       SOLE DISPOSITIVE POWER
                                                            0
                           8.       SHARED DISPOSITIVE POWER
                                                            656,900

9.       AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                  656,900

10.      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
         SHARES (See Instructions)                                           [ ]

11.      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

                  2.12%

12. TYPE OF REPORTING PERSON (See Instructions)

                  IN



-------------------                                           ------------------
CUSIP No. 766559603                   13G/A                   Page 4 of 10 Pages
-------------------                                           ------------------


1.       NAMES OF REPORTING PERSONS

         Mr. David Kroin

         I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):



2.       CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

         (a)      [ ]

         (b)      [ ]

--------------------------------------------------------------------------------
3.       SEC USE ONLY


--------------------------------------------------------------------------------

4.       CITIZENSHIP OR PLACE OF ORGANIZATION

         USA

NUMBER OF SHARES           5.       SOLE VOTING POWER
  BENEFICIALLY                                              0
 OWNED BY EACH             6.       SHARED VOTING POWER
REPORTING PERSON                                            656,900
      WITH                 7.       SOLE DISPOSITIVE POWER
                                                            0
                           8.       SHARED DISPOSITIVE POWER
                                                            656,900

9.       AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                  656,900

10.      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
         SHARES (See Instructions)                                           [ ]

11.      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

                  2.12%

12.      TYPE OF REPORTING PERSON (See Instructions)

                  IN



-------------------                                           ------------------
CUSIP No. 766559603                   13G/A                   Page 5 of 10 Pages
-------------------                                           ------------------


ITEM 1.

         (a)      Name of Issuer

                  Rigel Pharmaceuticals, Inc.

         (b)      Address of Issuer's Principal Executive Offices

                  1180 Veterans Blvd.
                  South San Francisco, CA  94082

ITEM 2.

         (a)      Name of Person Filing

                                    Great Point Partners, LLC
                                    Dr. Jeffrey M. Jay, M.D.
                                    Mr. David Kroin

                  The Reporting Persons have entered into a Joint Filing
                  Agreement, dated February 14, 2008, a copy of which is filed
                  with this Schedule 13G/A as Exhibit A, pursuant to which the
                  Reporting Persons have agreed to file this statement jointly
                  in accordance with the provisions of Rule 13d-1(k)(1) under
                  the Act.

         (b)      Address of Principal Business Office, or if none, Residence

                  The address of the principal business office of each of the
                  Reporting Persons is

                                    165 Mason Street, 3rd Floor
                                    Greenwich, CT 06830

         (c)      Citizenship

                  Great Point Partners, LLC is a limited liability company
                  organized under the laws of the State of Delaware. Dr. Jeffrey
                  M. Jay, M.D. is a citizen of the United States. Mr. David
                  Kroin is a citizen of the United States.

         (d)      Title of Class of Securities

                  Common Stock

         (e)      CUSIP Number

                  766559603

ITEM 3.  IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13D-1(b) OR 240.13D.2(b)
         OR (c), CHECK WHETHER THE PERSON FILING IS A:

                  Not Applicable.

         (a) [ ]  Broker or dealer registered under Section 15 of the Act (15
                  U.S.C. 78o)

         (b) [ ]  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

         (c) [ ]  Insurance company as defined in Section 3(a)(19) of the Act
                  (15. U.S.C. 78c).



-------------------                                           ------------------
CUSIP No. 766559603                   13G/A                   Page 6 of 10 Pages
-------------------                                           ------------------


         (d) [ ]  Investment Company registered under Section 8 of the
                  Investment Company Act of 1940 (15 U.S.C. 80a-8).

         (e) [ ]  An investment adviser in accordance with
                  ss.240.13d-1(b)(1)(ii)(E).

         (f) [ ]  An employee benefit plan or endowment fund in accordance with
                  ss.240.13d-1(b)(1)(ii)(F).

         (g) [ ]  A parent holding company or control person in accordance with
                  ss.240.13d-1(b)(1)(ii)(G).

         (h) [ ]  A savings associations as defined in Section 3(b) of the
                  Federal Deposit Insurance Act (12 U.S.C. 1813).

         (i) [ ]  A church plan that is excluded from the definition of an
                  investment company under Section 3(c)(14) of the Investment
                  Company Act of 1940 (15 U.S.C. 80a-3).

         (j) [ ]  Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).

ITEM 4.  OWNERSHIP

         Great Point Partners, LLC ("Great Point") is the investment manager of
         Biomedical Value Fund, L.P. ("BVF"), and by virtue of such status may
         be deemed to be the beneficial owner of the 354,724 shares of Common
         Stock of the Issuer owned by BVF (the "BVF Shares"). Each of Dr.
         Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great
         Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of
         Great Point, has voting and investment power with respect to the BVF
         Shares, and therefore may be deemed to be the beneficial owner of the
         BVF Shares.

         Great Point is the investment manager of Biomedical Offshore Value
         Fund, Ltd. ("BOVF"), and by virtue of such status may be deemed to be
         the beneficial owner of the 302,176 shares of Common Stock of the
         Issuer owned by BOVF (the "BOVF Shares"). Each of Dr. Jay, as senior
         managing member of Great Point, and Mr. Kroin, as special managing
         member of Great Point, has voting and investment power with respect to
         the BOVF Shares, and therefore may be deemed to be the beneficial owner
         of the BOVF Shares.

         Each of Great Point, Dr. Jay and Mr. Kroin disclaim beneficial
         ownership of the BVF Shares and the BOVF Shares, except to the extent
         of their respective pecuniary interest.


         Provide the following information regarding the aggregate number and
         percentage of the class of securities of the issuer identified in Item
         1.

         1.       GREAT POINT PARTNERS, LLC

         (a)      Amount beneficially owned: 656,900

         (b)      Percent of class: 2.12%

         (c)      Number of shares as to which the person has:

                  (i)      Sole power to vote or to direct the vote: - 0 -

                  (ii)     Shared power to vote or to direct the vote: 656,900



-------------------                                           ------------------
CUSIP No. 766559603                   13G/A                   Page 7 of 10 Pages
-------------------                                           ------------------


                  (iii)    Sole power to dispose or to direct the disposition
                           of: - 0 -

                  (iv)     Shared power to dispose or to direct the disposition
                           of: 656,900

         2.       DR. JEFFREY R. JAY, M.D.

         (a)      Amount beneficially owned: 656,900

         (b)      Percent of class: 2.12%

         (c)      Number of shares as to which the person has:

                  (i)      Sole power to vote or to direct the vote: 0

                  (ii)     Shared power to vote or to direct the vote: 656,900

                  (iii)    Sole power to dispose or to direct the disposition
                           of: 0

                  (iv)     Shared power to dispose or to direct the disposition
                           of: 656,900

         3.       MR. DAVID KROIN

         (a)      Amount beneficially owned: 656,900

         (b)      Percent of class: 2.12%

         (c)      Number of shares as to which the person has:

                  (i)      Sole power to vote or to direct the vote: 0

                  (ii)     Shared power to vote or to direct the vote: 656,900

                  (iii)    Sole power to dispose or to direct the disposition
                           of: 0

                  (iv)     Shared power to dispose or to direct the disposition
                           of: 656,900

ITEM 5.  OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

         If this statement is being filed to report the fact that as of the date
         hereof each of the Reporting Persons has ceased to be the beneficial
         owner of more than five percent of the class of securities, check the
         following [X].

ITEM 6.  OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

         See item 4.

ITEM 7.  IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
         SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

         Not Applicable.

ITEM 8.  IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

         Not Applicable.

ITEM 9.  NOTICE OF DISSOLUTION OF GROUP



-------------------                                           ------------------
CUSIP No. 766559603                   13G/A                   Page 8 of 10 Pages
-------------------                                           ------------------


         Not Applicable.

ITEM 10. CERTIFICATION

By signing below I certify that, to the best of my knowledge and belief, the
securities referred to above were not acquired and are not held for the purpose
of or with the effect of changing or influencing the control of the issuer of
the securities and were not acquired and are not held in connection with or as
participant in any transaction having that purpose or effect.



-------------------                                           ------------------
CUSIP No. 766559603                   13G/A                   Page 9 of 10 Pages
-------------------                                           ------------------


                                    SIGNATURE
                                    ---------

After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.

Date: February 14, 2008


                                        GREAT POINT PARTNERS, LLC

                                        By: /s/ Dr. Jeffrey R. Jay, M.D.
                                            ------------------------------------
                                            Dr. Jeffrey R. Jay, M.D.,
                                              as senior managing member

                                        /s/ Dr. Jeffrey R. Jay, M.D.
                                        ----------------------------------------
                                        DR. JEFFREY R. JAY, M.D.

                                        /s/ Mr. David Kroin
                                        ----------------------------------------
                                        MR. DAVID KROIN



                                                                       EXHIBIT A


             AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G/A


The undersigned hereby agree as follows:

         (i)      Each of them is individually eligible to use the Schedule
13G/A to which this Exhibit is attached, and such Schedule 13G/A is filed on
behalf of each of them; and

         (ii)     Each of them is responsible for the timely filing of such
Schedule 13G/A and any amendments thereto, and for the completeness and accuracy
of the information concerning such person contained therein; but none of them is
responsible for the completeness or accuracy of the information concerning the
other persons making the filing, unless such person knows or has reason to
believe that such information is inaccurate.

Date:  February 14, 2008


                                        GREAT POINT PARTNERS, LLC

                                        By: /s/ Dr. Jeffrey R. Jay, M.D.
                                            ------------------------------------
                                            Dr. Jeffrey R. Jay, M.D.,
                                              as senior managing member


                                        /s/ Dr. Jeffrey R. Jay, M.D.
                                        ----------------------------------------
                                        DR. JEFFREY R. JAY, M.D.

                                        /s/ Mr. David Kroin
                                        ----------------------------------------
                                        MR. DAVID KROIN